TaiGen Biopharmaceuticals Holdings Limited (TPEX: 4157)

TaiGen Biopharmaceuticals Holdings Revenue

TaiGen Biopharmaceuticals Holdings had revenue of 8.61M TWD in the quarter ending September 30, 2024, a decrease of -7.52%. This brings the company's revenue in the last twelve months to 148.75M, up 24.72% year-over-year. In the year 2023, TaiGen Biopharmaceuticals Holdings had annual revenue of 123.13M with 239.87% growth.

• Revenue (ttm): 148.75M
• Revenue Growth: +24.72%
• P/S Ratio: 60.55
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 9.04B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	123.13M	86.90M	239.87%
Dec 31, 2022	36.23M	-1.26B	-97.20%
Dec 31, 2021	1.29B	1.27B	5,426.95%
Dec 31, 2020	23.42M	3.11M	15.30%
Dec 31, 2019	20.31M	-9.30M	-31.41%